David Young - 01 Jan 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: Pres. Research & Development, Director
Signature: /s/ David Young by John J. Wolfel, as Attorney-in-Fact
Issuer symbol: PCSA
Transactions as of: 01 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 04 Feb 2026, 17:09:36 UTC
Previous filing: 03 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Young David	Pres. Research & Development, Director	C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	04 Feb 2026	0001378166

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Options Exercise	$0	+49	+0.56%	$0.000000	8,752	01 Jan 2026	Direct	F1
holding	PCSA	Common Stock						1,242	01 Jan 2026	By Young-Plaisance Revocable Trust
holding	PCSA	Common Stock						432	01 Jan 2026	By Family Entities
holding	PCSA	Common Stock						742	01 Jan 2026	By CorLyst, LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCSA	Restricted Stock Units	Options Exercise	$0	-49	-100%	$0.000000	0	01 Jan 2026	Common Stock	49	$0.000000	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Distribution of vested restricted shares.